- Title
- A Comprehensive Safety Assessment of Relacorilant: Insights From Phase 2 and Phase 3 Trials in Patients With Endogenous Hypercortisolism
- Creators
- Zeina C. Hannoush - University of Miami, Miller School of MedicineCorin Badiu - College Station Medical CenterMiguel Angel Mangas Cruz - Hosp Univ Virgen Del Rocio, Seville, SpainGeorgiana Dobri - Weill Cornell MedicineAleksandra Gilis-Januszewska - Jagiellonian UniversityAtanaska Elenkova - College Station Medical CenterAmir H. Hamrahian - Johns Hopkins UniversityFrancisco Jose Tinahones Madueno - Hosp Univ Virgen Victoria, Malaga, SpainJohn Parker - Wilmington Hlth Endocrinol, Accellacare Clin Res, Wilmington, NC USARosario Pivonello - University of Naples Federico IIGadi Shlomai - MED InstituteJeff Botbyl - Corcept Therapeut Inc, Redwood City, CA USAIulia Cristina Tudor - Corcept Therapeutics (United States)Andreas G. Moraitis - Corcept Therapeutics (United States)Amanda Kesner-Hays - Corcept Therapeutics (United States)
- Publication Details
- Endocrine practice, Vol.32(2)
- Publisher
- Elsevier
- Number of pages
- 1
- Academic Unit
- Miller School of Medicine; UMMG Dept of Medicine - Endocrinology, Diabetes & Metabolism
- Language
- English
- Resource Type
- Abstract
- Record Identifier
- 991033020808502976
Abstract
A Comprehensive Safety Assessment of Relacorilant: Insights From Phase 2 and Phase 3 Trials in Patients With Endogenous Hypercortisolism
Endocrine practice, Vol.32(2)
2026-02-01
Metrics
1 Record Views